Severity or Etiology?　― Reframing Cardiogenic Shock Management in the Era of Individualized Mechanical Circulatory Support ―

priate?These decisions involve a delicate trade-off between timeliness, hemodynamic cost, and complication risks.Despite several consensus statements from Japan, 1 W hen encountering patients with cardiogenic shock (CS), clinicians face complex decisions regarding the initiation and management of temporary mechanical circulatory support (tMCS): Should pharmacological therapy be attempted first?Should tMCS be initiated early?If so, which device is most appro-